Skip to content

Changes in migraine pathway - an MRI study

Changes in migraine pathway - an MRI study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00023764
Enrollment
80
Registered
2020-12-17
Start date
2020-11-30
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G43.0 G43.1

Interventions

Group 1: cMRI in all migraine patients with and without aura Group 2: Performing a cMRI 6 months after changing the prophylactic therapy- Patients who got an cMRI in Arm 1, will get a second cMRI afte

Sponsors

Klinik für Neurologie und Neurophysiologie Uniklinik Freiburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patient suffering from migraine with/without aura and with/without prophylaxis All migraine patients are included if they fulfill the following criteria: a.) episodic or chronic migraine with or without aura (had at least one attack in life) b.) female and male sex c.) < 65 years old

Exclusion criteria

Exclusion criteria: Excluded are all patients for whom the above does not apply, taking opiates (opiates act on the pain system and can falsify the cMRI data), patients suffering from further headaches or facial pain (except tension headache), pregnancy or lactation, contraindications against cMRI (pacemaker), other metal implants which are contraindicated and the lack of the possibility to oral and written information. Patients over 65 years are not included because they may develop more cardiovascular diseases and cerebral microvascular changes etc., which could falsify the MRI results.

Design outcomes

Primary

MeasureTime frame
Arm 1.) Significant changes in white and grey matter (pain matrix) in migraine patients (with and without aura) compared to healthy controls (diffusivity/voxel-based morphometry) Arm 2.) Significant changes in the pain matrix (diffusivity/voxel-based morphometry) due to migraine prophylaxis

Secondary

MeasureTime frame
Arm 1.) none Arm 2.) The changes in the accompanying symptoms (e.g. nausea/vomiting, photo-phonophobia, etc.) correlate with diffusivity/voxel-based morphometry

Countries

Germany

Contacts

Public ContactCharlotte von Kageneck

Klinik für Neurologie und Neurophysiologie Uniklinik Freiburg

charlotte.kageneck@unilkinik-freiburg.de076127050010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026